Over the past decade, SelectScience® has been at the forefront of sharing groundbreaking scientific research and innovations through exclusive video interviews with scientists. These interviews have provided valuable insights into various fields of scientific exploration, ranging from mass spectrometry and cancer diagnostics to stem cell research and liquid biopsy advancements.
In this article, we highlight some of the most influential video interviews of the past 10 years published on SelectScience, showcasing the cutting-edge discoveries and technologies that have shaped the scientific community. Read on to explore videos on biomarker discovery, precision medicine, quantitiave proteomics, and more.
Dr. Chris Whelan discusses how data from the UK Biobank – Pharma Proteomics Project has revealed new insights into associations between gene variants and protein concentrations. Whelan explains how this project is enabling new causal biomarkers for diseases to be identified as well as new drug targets with higher probabilities of success. The interview sheds light on how proteomics techniques can revolutionize drug discovery by enabling the identification of protein biomarkers and pathways associated with diseases.
Dr. Marzia Del Re from the University of Pisa discusses the potential of liquid biopsies for non-invasive cancer monitoring and personalized treatment selection. The interview underscores the importance of liquid biopsies in revolutionizing cancer diagnostics and treatment strategies.
Dr. Fay Nicolson, from the Dana-Farber Cancer Institute and Harvard Medical School, shares how she uses nanoparticles to precisely image cancer in pre-clinical animal models. Nicolson also explains why the lack of harmful, ionizing radiation makes Raman spectroscopy the technique of choice over other existing methods. This breakthrough has the potential to revolutionize early cancer detection and improve patient outcomes.
Jennifer O’Sullivan, MRC Weatherall Institute of Molecular Medicine, discusses her work researching why some blood cancers progress to a more advanced stage where there are currently limited therapies. O’Sullivan explains how by looking for changes within rare bone marrow stem cells it may be possible to target and develop new therapies for blood cancers.
Dr. Richard Kay, Senior Research Associate at the Wellcome-MRC Institute of Metabolic Science at the University of Cambridge, talks about how he uses mass spectrometry to measure gut hormone peptides related to diabetes. Kay outlines the challenges of detecting low-abundant peptides and explains the benefits of mass spectrometry over immunoassays. The interview highlights the significance of sensitive mass spectrometry methods in unraveling the complexities of gut hormone signaling.
Lukas Uebbing and Vera Cornet, pharmacists and Ph.D. students at the Johannes Gutenberg University of Mainz, Germany, discuss their research using liposomal formulations and the creation of mRNA lipoplex preparations to deliver mRNA to target cells. The interview sheds light on the transformative role of mRNA-based therapeutics in precision medicine.
Michael MacCoss, professor of genome sciences at the University of Washington describes his work developing technologies to quantitatively measure proteins in complex matrices, and how his collaboration with 908 Devices is aiming to improve the speed and robustness of these measurements using capillary electrophoresis-mass spectrometry (CE-MS). The interview showcases the versatility of CE-MS and its role in advancing proteomics investigations.
Corbin Occhino, Senior Scientist at Tyra Biosciences, shares how automation has transformed the way the precision oncology company manages its compound libraries, bringing increased throughput and reduced labor. The interview showcases how automation and advanced sample handling technologies can accelerate drug discovery workflows, enabling high-throughput screening and efficient compound management.